Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts
Malignant mesothelioma (MM) is a rare disease often associated with environmental exposure to asbestos and other erionite fibers. MM has a long latency period prior to manifestation and a poor prognosis. The survival post-diagnosis is often less than a year. Although use of asbestos has been banned...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-07-01
|
| Series: | Frontiers in Genetics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fgene.2018.00232/full |
| _version_ | 1811230694609780736 |
|---|---|
| author | Noushin Nabavi Noushin Nabavi Jingchao Wei Jingchao Wei Dong Lin Dong Lin Colin C. Collins Peter W. Gout Yuzhuo Wang Yuzhuo Wang |
| author_facet | Noushin Nabavi Noushin Nabavi Jingchao Wei Jingchao Wei Dong Lin Dong Lin Colin C. Collins Peter W. Gout Yuzhuo Wang Yuzhuo Wang |
| author_sort | Noushin Nabavi |
| collection | DOAJ |
| description | Malignant mesothelioma (MM) is a rare disease often associated with environmental exposure to asbestos and other erionite fibers. MM has a long latency period prior to manifestation and a poor prognosis. The survival post-diagnosis is often less than a year. Although use of asbestos has been banned in the United States and many European countries, asbestos is still being used and extracted in many developing countries. Occupational exposure to asbestos, mining, and migration are reasons that we expect to continue to see growing incidence of mesothelioma in the coming decades. Despite improvements in survival achieved with multimodal therapies and cytoreductive surgeries, less morbid, more effective interventions are needed. Thus, identifying prognostic and predictive biomarkers for MM, and developing novel agents for targeted therapy, are key unmet needs in mesothelioma research and treatment. In this review, we discuss the evolution of pre-clinical model systems developed to study MM and emphasize the remarkable capability of patient-derived xenograft (PDX) MM models in expediting the pre-clinical development of novel therapeutic approaches. PDX disease model systems retain major characteristics of original malignancies with high fidelity, including molecular, histopathological and functional heterogeneities, and as such play major roles in translational research, drug development, and precision medicine. |
| first_indexed | 2024-04-12T10:32:36Z |
| format | Article |
| id | doaj.art-52f420d41d6a47bca3d26e431390ae15 |
| institution | Directory Open Access Journal |
| issn | 1664-8021 |
| language | English |
| last_indexed | 2024-04-12T10:32:36Z |
| publishDate | 2018-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Genetics |
| spelling | doaj.art-52f420d41d6a47bca3d26e431390ae152022-12-22T03:36:48ZengFrontiers Media S.A.Frontiers in Genetics1664-80212018-07-01910.3389/fgene.2018.00232353470Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer XenograftsNoushin Nabavi0Noushin Nabavi1Jingchao Wei2Jingchao Wei3Dong Lin4Dong Lin5Colin C. Collins6Peter W. Gout7Yuzhuo Wang8Yuzhuo Wang9Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, CanadaDepartment of Experimental Therapeutics, BC Cancer Research Centre, Vancouver, BC, CanadaDepartment of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, CanadaDepartment of Urology, the Third Xiangya Hospital, Central South UniversityChangsha, ChinaDepartment of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, CanadaDepartment of Experimental Therapeutics, BC Cancer Research Centre, Vancouver, BC, CanadaDepartment of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, CanadaDepartment of Experimental Therapeutics, BC Cancer Research Centre, Vancouver, BC, CanadaDepartment of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, CanadaDepartment of Experimental Therapeutics, BC Cancer Research Centre, Vancouver, BC, CanadaMalignant mesothelioma (MM) is a rare disease often associated with environmental exposure to asbestos and other erionite fibers. MM has a long latency period prior to manifestation and a poor prognosis. The survival post-diagnosis is often less than a year. Although use of asbestos has been banned in the United States and many European countries, asbestos is still being used and extracted in many developing countries. Occupational exposure to asbestos, mining, and migration are reasons that we expect to continue to see growing incidence of mesothelioma in the coming decades. Despite improvements in survival achieved with multimodal therapies and cytoreductive surgeries, less morbid, more effective interventions are needed. Thus, identifying prognostic and predictive biomarkers for MM, and developing novel agents for targeted therapy, are key unmet needs in mesothelioma research and treatment. In this review, we discuss the evolution of pre-clinical model systems developed to study MM and emphasize the remarkable capability of patient-derived xenograft (PDX) MM models in expediting the pre-clinical development of novel therapeutic approaches. PDX disease model systems retain major characteristics of original malignancies with high fidelity, including molecular, histopathological and functional heterogeneities, and as such play major roles in translational research, drug development, and precision medicine.https://www.frontiersin.org/article/10.3389/fgene.2018.00232/fullrare diseasesgenomicspatient-derived xenograftsmalignant mesotheliomapre-clinical cancer researchdrug development |
| spellingShingle | Noushin Nabavi Noushin Nabavi Jingchao Wei Jingchao Wei Dong Lin Dong Lin Colin C. Collins Peter W. Gout Yuzhuo Wang Yuzhuo Wang Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts Frontiers in Genetics rare diseases genomics patient-derived xenografts malignant mesothelioma pre-clinical cancer research drug development |
| title | Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts |
| title_full | Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts |
| title_fullStr | Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts |
| title_full_unstemmed | Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts |
| title_short | Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts |
| title_sort | pre clinical models for malignant mesothelioma research from chemical induced to patient derived cancer xenografts |
| topic | rare diseases genomics patient-derived xenografts malignant mesothelioma pre-clinical cancer research drug development |
| url | https://www.frontiersin.org/article/10.3389/fgene.2018.00232/full |
| work_keys_str_mv | AT noushinnabavi preclinicalmodelsformalignantmesotheliomaresearchfromchemicalinducedtopatientderivedcancerxenografts AT noushinnabavi preclinicalmodelsformalignantmesotheliomaresearchfromchemicalinducedtopatientderivedcancerxenografts AT jingchaowei preclinicalmodelsformalignantmesotheliomaresearchfromchemicalinducedtopatientderivedcancerxenografts AT jingchaowei preclinicalmodelsformalignantmesotheliomaresearchfromchemicalinducedtopatientderivedcancerxenografts AT donglin preclinicalmodelsformalignantmesotheliomaresearchfromchemicalinducedtopatientderivedcancerxenografts AT donglin preclinicalmodelsformalignantmesotheliomaresearchfromchemicalinducedtopatientderivedcancerxenografts AT colinccollins preclinicalmodelsformalignantmesotheliomaresearchfromchemicalinducedtopatientderivedcancerxenografts AT peterwgout preclinicalmodelsformalignantmesotheliomaresearchfromchemicalinducedtopatientderivedcancerxenografts AT yuzhuowang preclinicalmodelsformalignantmesotheliomaresearchfromchemicalinducedtopatientderivedcancerxenografts AT yuzhuowang preclinicalmodelsformalignantmesotheliomaresearchfromchemicalinducedtopatientderivedcancerxenografts |